
    
      Multi-center, single-arm, open-label,phase II study to investigate efficacy and safety of
      Flumatinib in Chinese patients with accelerated or blastic Phase chronic myelogenous
      leukemia. The starting daily oral dose of Flumatinib is 600mgï¼Œcore test is six cycles (each
      cycle is 28 days), collecting the core test data for primary efficacy analysis. The longest
      treatment time is 12 cycles.
    
  